Gastric sleeve surgery vs gastric balloon is one of the most common comparisons patients face when exploring weight loss treatment options in the UK. Both interventions aim to reduce food intake and support meaningful weight loss, but they differ significantly in their mechanism, invasiveness, reversibility, and long-term outcomes. Sleeve gastrectomy is a permanent surgical procedure, whilst the gastric balloon is a temporary, non-surgical device. Understanding these differences — alongside NHS eligibility criteria, safety profiles, and recovery expectations — is essential for making an informed decision with your clinical team.

How Gastric Sleeve Surgery and Gastric Balloon Work

Sleeve gastrectomy permanently removes 75–80% of the stomach and alters gut hormones, whilst the gastric balloon is a temporary, non-surgical silicone device that occupies stomach space to promote early fullness.

Gastric sleeve surgery, formally known as sleeve gastrectomy, is a permanent surgical procedure in which approximately 75–80% of the stomach is removed, leaving a narrow, tube-shaped 'sleeve'. This significantly reduces the stomach's capacity, limiting the volume of food that can be consumed at one time. Beyond restriction, the procedure also removes the fundus of the stomach — the region primarily responsible for producing ghrelin, a hormone that stimulates hunger. Additionally, sleeve gastrectomy alters the release of other gut hormones, including GLP-1 and PYY, which contribute to improved satiety and appetite regulation. This combination of reduced capacity and hormonal change supports sustained weight loss over time.

The gastric balloon is a non-surgical, temporary intervention. A soft silicone balloon is placed into the stomach and inflated with saline solution, occupying space within the stomach and promoting an earlier sense of fullness. Several types are available in the UK. Some balloons — such as the Orbera — are inserted and removed endoscopically and may remain in place for six to twelve months. Others, such as the Allurion balloon, are swallowed as a capsule without the need for endoscopy or sedation and pass spontaneously after approximately sixteen weeks. The Spatz3 balloon is an adjustable endoscopic device that can remain in situ for up to twelve months. Patients should note that device availability may vary, and the clinical team will advise on which options are currently accessible.

The key distinction between the two procedures lies in their permanence and mechanism:

• Gastric sleeve: Surgical, irreversible, structural change to the stomach

• Gastric balloon: Non-surgical, reversible, temporary space-occupying device; placement and removal routes vary by device type

Both interventions are intended to support calorie restriction and behaviour change, but they differ substantially in their invasiveness, duration of effect, and suitability for different patient groups. Understanding these mechanisms helps patients and clinicians make informed, individualised decisions.

Eligibility Criteria and NHS Referral Pathways

NHS sleeve gastrectomy is funded for adults with a BMI of 40 kg/m² or above under NICE CG189; the gastric balloon is not routinely NHS-commissioned and is usually accessed privately.

Access to bariatric interventions on the NHS is governed by NICE Clinical Guideline CG189 (Obesity: identification, assessment and management), which sets out clear eligibility thresholds. For gastric sleeve surgery, NHS funding is typically considered for adults with a BMI of 40 kg/m² or above, or a BMI of 35–39.9 kg/m² in the presence of a significant obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. NICE CG189 also recommends that bariatric surgery be considered for adults with a BMI of 30–34.9 kg/m² who have recent-onset type 2 diabetes (diagnosed within the preceding ten years), where surgery may offer the best chance of achieving remission.

It is important to note that lower BMI thresholds apply for people of Asian family origin, as the health risks associated with excess weight occur at a lower BMI in this population. Clinicians typically apply a threshold approximately 2.5 kg/m² lower than the standard criteria. Patients are generally expected to have completed a structured weight management programme and demonstrated commitment to long-term lifestyle change.

NHS bariatric services are organised into tiers. Patients are usually referred first to a Tier 3 specialist weight management service for intensive, multidisciplinary support before progressing to Tier 4 bariatric surgery services. Referral typically begins with the GP, who will assess BMI, comorbidities, and previous weight management history. Multidisciplinary team (MDT) review — including dietetic and psychological assessment — is required before any bariatric procedure is approved.

Commissioning policies can vary by Integrated Care Board (ICB), and patients are advised to check their local pathway. The gastric balloon is not routinely commissioned by the NHS and is more commonly accessed through private healthcare providers, though it may be considered in specific clinical contexts — for example, as a bridge intervention to reduce surgical risk in patients with very high BMIs prior to bariatric surgery.

For those considering private treatment, it is important to ensure the provider is regulated by the Care Quality Commission (CQC) and that the clinical team includes dietetic and psychological support alongside surgical expertise.

Comparing Weight Loss Outcomes and Effectiveness

Sleeve gastrectomy produces approximately 25–35% total body weight loss sustained over five years, whilst the gastric balloon achieves a more modest 7–15% during the treatment period with a risk of weight regain after removal.

In terms of weight loss outcomes, gastric sleeve surgery consistently demonstrates superior and more durable results compared to the gastric balloon. Clinical evidence, including data from the National Bariatric Surgery Registry (NBSR), suggests that patients undergoing sleeve gastrectomy can expect to lose approximately 25–35% of their total body weight (TBWL) within one to two years post-operatively, which corresponds to roughly 60–70% of excess body weight (EWL). Long-term data indicate that meaningful weight loss is maintained in the majority of patients at five years, particularly when supported by lifestyle intervention.

The gastric balloon produces more modest results. Studies report an average TBWL of approximately 7–15% during the treatment period, with variation depending on the device used and the patient's engagement with the accompanying dietary and behavioural programme. Weight regain following balloon removal is a recognised concern, and outcomes are heavily dependent on sustained lifestyle change. The balloon is therefore best understood as a tool to initiate weight loss and establish healthier habits, rather than a standalone long-term solution.

Beyond weight loss, sleeve gastrectomy is associated with significant improvements in obesity-related comorbidities:

• Type 2 diabetes: Remission or improvement in glycaemic control is well documented

• Hypertension: Blood pressure reduction is commonly observed

• Sleep apnoea: Symptoms frequently improve with substantial weight loss

The gastric balloon may also contribute to modest improvements in metabolic parameters during the treatment period, though these benefits are less pronounced and less sustained. When comparing the two options, it is important to contextualise outcomes within the individual patient's health goals, risk profile, and capacity for long-term follow-up — factors that should be explored thoroughly with the clinical team.

Risks, Side Effects and Safety Considerations

Sleeve gastrectomy carries surgical risks including staple line leak and GORD; the gastric balloon risks include deflation, migration, and gastrointestinal perforation, with MHRA safety guidance in place for balloon devices.

As with any medical intervention, both gastric sleeve surgery and the gastric balloon carry associated risks, and patients should receive thorough pre-procedure counselling to ensure informed consent.

Gastric sleeve surgery, as a major abdominal operation typically performed laparoscopically, carries the risks inherent to general anaesthesia and surgery. These include:

• Staple line leak: A serious but uncommon complication; rates of approximately 1% are reported in experienced UK centres, though figures vary

• Bleeding and infection

• Venous thromboembolism (VTE): DVT and pulmonary embolism are recognised risks of major abdominal surgery; standard prophylaxis measures include early mobilisation and thromboprophylaxis, as directed by the clinical team

• Gastro-oesophageal reflux disease (GORD): A well-recognised long-term concern, as the procedure can worsen or precipitate reflux symptoms

• Nutritional deficiencies: Including vitamin B12, iron, folate, and vitamin D — lifelong supplementation is required

• Gallstone formation: Rapid weight loss increases the risk of gallstones; patients should be aware of this and discuss monitoring or preventive options with their clinical team

• Stricture or stenosis of the sleeve in rare cases

The gastric balloon carries a lower procedural risk profile given its non-surgical nature, but it is not without complications. Common side effects in the days following insertion include nausea, vomiting, abdominal cramping, and reflux, which typically settle within one to two weeks. Proton pump inhibitor (PPI) therapy is commonly prescribed while the balloon is in situ to reduce reflux symptoms, in line with local clinical protocols. More serious but less frequent risks include:

• Balloon deflation and migration, which can cause intestinal obstruction

• Spontaneous hyperinflation of the balloon (rare)

• Oesophageal or gastric perforation during insertion or removal

• Acute pancreatitis (rare)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued safety communications regarding intragastric balloons, highlighting the importance of patient selection and monitoring. Patients should be advised to seek urgent medical attention if they experience severe abdominal pain, persistent vomiting, or signs of balloon deflation (such as sudden increased hunger). Suspected adverse effects or device-related problems should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Both procedures require ongoing clinical oversight to manage complications promptly.

Recovery, Lifestyle Changes and Long-Term Support

Gastric sleeve recovery requires one to two nights in hospital and two to four weeks off work, with lifelong supplementation; gastric balloon patients typically return home the same day but still require structured dietary and behavioural support.

Recovery trajectories differ considerably between the two interventions. Following gastric sleeve surgery, patients are typically hospitalised for one to two nights and advised to take two to four weeks off work, depending on the nature of their employment. A staged dietary progression is followed post-operatively — beginning with fluids, advancing to purées, soft foods, and eventually a modified solid diet over approximately six to eight weeks. Physical activity is gradually reintroduced, with most patients resuming light exercise within four weeks.

Recovery from gastric balloon insertion is considerably shorter. Most patients return home the same day and resume normal activities within a few days, once the initial side effects of nausea and discomfort have settled. However, the relative ease of recovery should not diminish the importance of the accompanying lifestyle programme — dietary guidance and behavioural support are essential to maximising outcomes and preventing weight regain after balloon removal.

Experiencing these side effects? Our pharmacists can help you navigate them →

For both interventions, long-term success is closely tied to sustained lifestyle modification:

• Dietary changes: Smaller, nutrient-dense meals; avoidance of high-calorie liquids and snacking

• Physical activity: Regular moderate exercise is strongly encouraged

• Psychological support: Addressing emotional eating and building a healthy relationship with food

• Follow-up appointments: Regular monitoring with a dietitian, specialist nurse, and GP

Following sleeve gastrectomy, lifelong nutritional supplementation is mandatory. In line with BOMSS (British Obesity and Metabolic Surgery Society) guidance, patients typically require supplementation with a complete multivitamin and mineral preparation, vitamin D, calcium, vitamin B12, and iron (the latter particularly in women of childbearing age). Annual blood tests to monitor micronutrient levels are recommended as a minimum, with more frequent monitoring in the early post-operative period.

Patients who have undergone bariatric surgery are generally advised to avoid pregnancy for at least 12–18 months post-operatively, until weight has stabilised and nutritional status is optimised. Effective contraception should be discussed with the clinical team prior to and following surgery, as the absorption of oral contraceptives may be affected.

Patients should be aware that bariatric surgery is a tool, not a cure — sustained engagement with support services is the cornerstone of long-term weight management.

Choosing the Right Option With Your Clinical Team

Sleeve gastrectomy suits patients meeting NICE surgical criteria with significant comorbidities, whilst the gastric balloon is better suited to those avoiding surgery, not yet meeting BMI thresholds, or requiring pre-surgical risk reduction.

The decision between gastric sleeve surgery and a gastric balloon is not one-size-fits-all, and should always be made collaboratively within a multidisciplinary clinical framework. Several factors will influence which intervention — if either — is most appropriate for an individual patient.

Gastric sleeve surgery is generally better suited to patients who:

• Meet NICE CG189 eligibility criteria for bariatric surgery

• Have significant obesity-related comorbidities requiring substantial, durable weight loss

• Are medically fit for general anaesthesia and surgery

• Are committed to lifelong dietary change and supplementation

The gastric balloon may be more appropriate for patients who:

• Do not yet meet the BMI threshold for surgery, or wish to avoid surgery

• Require a lower-risk, reversible option

• Are seeking a structured, time-limited intervention to initiate weight loss

• Need to reduce surgical risk prior to a planned bariatric procedure

Patients with significant GORD or oesophagitis should discuss this carefully with their surgeon, as these conditions may influence the choice between sleeve gastrectomy and alternative procedures such as Roux-en-Y gastric bypass or one-anastomosis gastric bypass (OAGB), which may be more appropriate in this context.

Contraindications to intragastric balloon placement include large hiatus hernia, prior major upper gastrointestinal surgery, active inflammatory gastrointestinal disease, use of anticoagulant therapy, and pregnancy, among others. A thorough pre-treatment assessment will identify any such contraindications.

Pre-operative optimisation is an important part of the pathway. Patients will typically be asked to stop smoking, reduce alcohol intake, and engage with psychological screening before any bariatric procedure is approved. Smoking cessation is particularly important, as smoking significantly increases the risk of surgical complications.

It is also worth noting that some patients may not be suitable for either intervention. A thorough pre-treatment assessment, including medical history, psychological evaluation, and dietetic review, is essential before any decision is made.

Patients are encouraged to ask their clinical team about the full range of bariatric options available and to seek clarity on what post-procedure support will be provided. Reputable services — whether NHS or private — should offer structured follow-up as a standard component of care. If you are considering either procedure, the first step is a conversation with your GP, who can assess your suitability and initiate an appropriate referral pathway.

Frequently Asked Questions